dc.contributor.author | Filippatos, T. D. | en |
dc.contributor.author | Liberopoulos, E. N. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Elisaf, Moses S. | en |
dc.contributor.author | Mikhailidis, Dimitri P. | en |
dc.creator | Filippatos, T. D. | en |
dc.creator | Liberopoulos, E. N. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Elisaf, Moses S. | en |
dc.creator | Mikhailidis, Dimitri P. | en |
dc.date.accessioned | 2018-06-22T09:53:01Z | |
dc.date.available | 2018-06-22T09:53:01Z | |
dc.date.issued | 2009 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41614 | |
dc.description.abstract | Patients with malignant disease may need hormonal therapy as primary or adjuvant treatment or for palliation. Oestrogens usually decrease serum levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), increase high density lipoprotein cholesterol (HDL-C) concentration, but induce an elevation in serum triglyceride (TG) levels. Progestogens in the short-term decrease TC, LDL-C and HDL-C concentrations, and increase TG levels. In long-term treatment, progestogens usually have a small impact on lipid profile. Tamoxifen induces a decrease in TC and LDL-C levels, an increase in TG concentration, whereas either an increase, decrease or no change has been reported for HDL-C levels. Aromatase inhibitors induce an elevation, reduction or no change in lipid variables. These results depend mainly on the trial design, i.e. whether patients received prior treatment with tamoxifen or not and the duration of therapy. Gonadorelin analogues increase all lipid variables, but LDL-C alterations are usually non-significant. Anti-androgens usually decrease TC, LDL-C and HDL-C levels, whereas TG alterations vary. Information regarding the effects on lipid profile of somatostatin analogues is available almost exclusively in patients with acromegaly. In these patients somatostatin analogues usually induce no change or a decrease in TC and LDL-C levels, whereas they increase HDL-C and decrease TG serum concentrations. Oncologists should consider the lifestyle changes, and if needed hypolipidemic treatment, used to lower cardiovascular risk in non-cancer patients. Tamoxifen may rarely cause serious TG-related side effects, like acute pancreatitis. © 2008 Elsevier Ltd. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Cancer treatment reviews | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Drug response | en |
dc.subject | Prognosis | en |
dc.subject | Clinical trial | en |
dc.subject | Review | en |
dc.subject | Unindexed drug | en |
dc.subject | Medroxyprogesterone | en |
dc.subject | Drug megadose | en |
dc.subject | Placebo | en |
dc.subject | Risk factor | en |
dc.subject | Prostate cancer | en |
dc.subject | Cardiovascular risk | en |
dc.subject | Cholesterol | en |
dc.subject | Low density lipoprotein cholesterol | en |
dc.subject | Drug blood level | en |
dc.subject | Aromatase inhibitor | en |
dc.subject | Cancer hormone therapy | en |
dc.subject | Letrozole | en |
dc.subject | Hormonal | en |
dc.subject | Unspecified side effect | en |
dc.subject | Thrombosis | en |
dc.subject | Clinical trials as topic | en |
dc.subject | Cholesterol blood level | en |
dc.subject | Tamoxifen | en |
dc.subject | Hypercholesterolemia | en |
dc.subject | Lipid | en |
dc.subject | Lipid blood level | en |
dc.subject | Lipids | en |
dc.subject | Triglycerides | en |
dc.subject | Hypertriglyceridemia | en |
dc.subject | Adjuvant therapy | en |
dc.subject | Anastrozole | en |
dc.subject | Anti-androgens | en |
dc.subject | Antiandrogen | en |
dc.subject | Apolipoproteins | en |
dc.subject | Aromatase inhibitors | en |
dc.subject | Cardiovascular disease | en |
dc.subject | Conjugated estrogen | en |
dc.subject | Danazol | en |
dc.subject | Diethylstilbestrol | en |
dc.subject | Endometriosis | en |
dc.subject | Endometrium cancer | en |
dc.subject | Estrogen | en |
dc.subject | Ethinylestradiol | en |
dc.subject | Exemestane | en |
dc.subject | Gestagen | en |
dc.subject | Gonadorelin analogues | en |
dc.subject | Gonadorelin derivative | en |
dc.subject | High density lipoprotein cholesterol | en |
dc.subject | Hormone antagonist | en |
dc.subject | Leuprorelin | en |
dc.subject | Levonorgestrel | en |
dc.subject | Lipoproteins | en |
dc.subject | Lynestrenol | en |
dc.subject | Medroxyprogesterone acetate | en |
dc.subject | Norethisterone acetate | en |
dc.subject | Oestrogens | en |
dc.subject | Ovariectomy | en |
dc.subject | Polyestradiol | en |
dc.subject | Polyestradiol phosphate | en |
dc.subject | Progestogens | en |
dc.subject | Prostate surgery | en |
dc.subject | Somatostatin analogues | en |
dc.subject | Somatostatin derivative | en |
dc.subject | Toremifene | en |
dc.title | Effects of hormonal treatment on lipids in patients with cancer | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.ctrv.2008.09.007 | |
dc.description.volume | 35 | |
dc.description.issue | 2 | |
dc.description.startingpage | 175 | |
dc.description.endingpage | 184 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Elisaf, Moses S. [0000-0003-0505-078X] | |
dc.contributor.orcid | Filippatos, T. D. [0000-0002-1713-0923] | |
dc.contributor.orcid | Liberopoulos, E. N. [0000-0002-7162-3323] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0003-0505-078X | |
dc.gnosis.orcid | 0000-0002-1713-0923 | |
dc.gnosis.orcid | 0000-0002-7162-3323 | |